

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



ARCHIVOS DE Bronconeumología



www.archbronconeumol.org

Original Article

Clinical and Epidemiological Correlates of Low IFN-Gamma Responses in Mitogen Tube of QuantiFERON Assay in Tuberculosis Infection Screening During the COVID-19 Pandemic: A Population-Based Marker of COVID-19 Mortality?



Juan-José Palacios-Gutiérrez^{a,o}, Azucena Rodríguez-Guardado^{b,o}, Miguel Arias-Guillén^{c,o,q}, Rebeca Alonso-Arias^{d,o}, Sergio Palacios-Penedo^e, José-María García-García^f, Milagros Balbín^{g,o,p}, Dolores Pérez-Hernández^h, Marta Sandoval-Torrientesⁱ, Aurora Torreblanca-Gil^j, Santiago Melón^{k,o}, Víctor Asensi-Álvarez¹, Jeremy M. Clain^{m,n}, Patricio Escalante^{m,n,*}

^a Unidad de Referencia Regional de Micobacterias, AGC Laboratorio de Medicina, Hospital Universitario Central de Asturias, Oviedo, Spain

^b Unidad de Enfermedades Infecciosas, Hospital Universitario de Cabueñes, Gijón, Spain

^c Servicio de Neumología, Hospital Universitario Central de Asturias.Facultad de Medicina, Universidad de Oviedo, Spain

^d Servicio de Inmunología, AGC Laboratorio de Medicina, Hospital Universitario Central de Asturias, Oviedo, Spain

e Programa de Doctorado en Ciencias de la Salud, Universidad de Oviedo. Enfermedades Infecciosas, Departamento de Medicina, Facultad de Medicina, Universidad de Oviedo, Spain

^f Servicio de Neumología, Hospital Universitario San Agustín, Avilés, Spain

^g Servicio de Oncología Molecular, AGC Laboratorio de Medicina, Hospital Universitario Central de Asturias, Oviedo, Spain

^h Servicio de Vigilancia Epidemiológica, Dirección General de Salud Pública, Consejería de Salud Principado de Asturias, Spain

ⁱ Servicio de Microbiología, AGC Laboratorio de Medicina, Hopital Universitario Central de Asturias, Oviedo, Spain

^j Servicio de Microbiología, Hospital Universitario de Cabueñes, Gijón, Spain

^k Sección de Virología, Servicio de Microbiología, AGC Laboratorio de Medicina, Hospital Universitario Central de Asturias, Oviedo, Spain

¹ Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario Central de Asturias, Facultad de Medicina, Universidad de Oviedo, Spain

^m Mayo Mycobacteria and Bronchiectasis Clinic, Rochester, Minnesota, USA

ⁿ Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA

^o Instituto de Investigación Sanitaria del Principado de Asturias (ISPA)

^p Instituto Universitario de Oncología del Principado de Asturias (IUOPA)

^q CIBER-Enfermedades Respiratorias (ISCIII)

ARTICLE INFO

Article history: Received 16 November 2021 Accepted 16 January 2022 Available online 13 February 2022

Keywords: IGRA COVID-19 pneumonia Latent Tuberculosis Infection SARS-CoV-2 Phytohemagglutinin

ABSTRACT

Background: The clinical and epidemiological implications of abnormal immune responses in COVID-19 for latent tuberculosis infection (LTBI) screening are unclear.

Methods: We reviewed QuantiFERON TB Gold Plus (QFT-Plus) results (36,709 patients) from July 2016 until October 2021 in Asturias (Spain). We also studied a cohort of ninety hospitalized patients with suspected/confirmed COVID-19 pneumonia and a group of elderly hospitalized patients with COVID-19 who underwent serial QFT-Plus and immune profiling testing.

Results: The indeterminate QFT-Plus results rate went from 1.4% (July 2016 to November 2019) to 4.2% during the COVID-19 pandemic. The evolution of the number of cases with low/very low interferon-gamma (IFN-gamma) response in the mitogen tube paralleled the disease activity and number of deaths during the pandemic waves in our region (from March 2020 to October 2021). The percentages of positive QFT-plus patients did not significantly change before and during the pandemic (13.9% vs. 12.2%). Forty-nine patients from the suspected/confirmed COVID-19 pneumonia cohort (54.4%) had low/very low IFN-gamma response to mitogen, 22 of them (24.4%) had severe and critical pneumonia. None received immunosuppressants prior to testing. Abnormal radiological findings (P = 0.01) but not COVID-19 severity was associated with low mitogen response. Immune profiling showed a reduction of CD8 +T cells and a direct correlation between the number of EMRA CD8 +T-cells and IFN-gamma response to mitogen (P = 0.03).

Conclusion: Low IFN-gamma responses in mitogen tube of QFT-Plus often occur in COVID-19 pneumonia, which is associated with a low number of an effector CD8+T-cell subset and does not seem to affect LTBI screening; however, this abnormality seems to parallel the dynamics of COVID-19 at the population level and its mortality.

© 2022 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

* Corresponding author. Associate Professor of Medicine Division of Pulmonary and Critical Care Medicine, Mayo Clinic 200 First Street SW Rochester, MN 55905, USA Escalante.

E-mail address: Escalante.Patricio@mayo.edu (P. Escalante).

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) has become a worldwide public health emergency since its appearance in December 2019¹. Optimal treatment for COVID-19 remains challenging but some progress has been made ². In severe COVID-19, the use of corticosteroids has been associated with improvement in treatment outcomes. Other immunosuppressive and biological agents have been used empirically or in clinical trials for severe and critical COVID-19. The risk of opportunistic infections and reactivation of tuberculosis (TB) in patients undergoing these treatments remains unclear but some TB cases have been reported ^{3–5}. The use of Interferon gamma release assays (IGRAs) has become a routine practice for screening and diagnosis of latent tuberculosis infection (LTBI) in high-income and low-TB incidence settings ⁶.

IGRAs measure the release of interferon gamma (IFN- γ) in response to stimulation with specific *M. tuberculosis* (Mtb) antigens (i.e. ESAT-6 and CFP-10) in peripheral blood samples. QuantiFERON TB Gold PlusTM (QFT-Plus) is the latest version of ELISA-based IGRA platform that contains two Mtb-antigen tubes that combined elicits both CD4 and CD8 antigen-specific T cell responses. This *ex vivo* diagnostic platform includes a negative control tube and a positive control tube (mitogen), the latter of which allows measuring IFN- γ release in blood in response to a non-specific lymphocyte activator (i.e. phytohemagglutinin [PHA], a lectin, a type of glycoprotein).

The QFT-Plus assay is currently the most commonly utilized IGRA test in Asturias, Spain. Since December of 2019, and especially in the winter and early spring of 2020, we have observed an unusual increase in the number of OFT-Plus test results with low IFN- γ responses in the mitogen control tube and indeterminate QFT-Plus test results. This period coincides with the time of the COVID-19 pandemic in our region in Spain (Asturias). In this context, we hypothesized that this unprecedented increase in the number of low IFN-y responses to PHA was related to an unidentified biological effect of COVID-19 or its treatment. To investigate further, we measured the frequency of this unusual IGRA testing result and studied the potential factors associated with low IFN- γ responses to PHA. Specifically, we prospectively reviewed charts and measured sequential PHA responses in blood T cell subsets in a cohort of hospitalized patients with suspected or confirmed COVID-19 pneumonia during the peak of the COVID-19 pandemic.

Methods

Study subjects and setting

We conducted an observational study at the Hospital Universitario Central de Asturias (Oviedo, Spain) in the Principado de Asturias, a region of northern Spain with a population of one million inhabitants, and with a TB incidence rate of 10 cases per 100,000 population. A research ethics committee of the Principado de Asturias approved this study, and all hospitalized patients in the prospective part of the study signed an informed written consent. In this region, all IGRA tests are centrally processed at the referral Mycobacteria laboratory of the Hospital Universitario Central de Asturias, which serves all 8 public hospitals in the region. We reviewed all testing results and ordering indications of all QFT-Plus (from 36,709 patients) conducted in our referral laboratory from July 2016 until October 2021. We also reviewed all charts of patients hospitalized in our referral center with clinical or radiological evidence of pneumonia, and/or acute respiratory distress for two weeks in March 2020, which coincided with the time of the first COVID-19 epidemic wave in the Asturias region.

SARS-CoV-2 diagnostic testing

For molecular COVID-19 diagnosis, we used a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) directed to two targets located in the ORF1ab and N regions of the SARS-CoV-2. Samples from the upper (nasopharyngeal swab) and/or lower (sputum or tracheobronchial aspirate) respiratory tract were analyzed. The human beta-globin gene was utilized as the internal control for this RT-PCR assay.

For serologic diagnosis, a chemiluminescent immunoassay (CLIA) for the qualitative detection of IgM and IgG antibodies to SARS-CoV-2 was used (DiaSorin, LIAISON[®] SARS-CoV-2 IgM and LIAISON[®] SARS-CoV-2 S1/S2 IgG).

COVID-19 disease severity definition

For the hospitalized patient cohort, COVID-19 disease severity was classified as either non-severe (mild to moderate) and severe (including critical) based on a modified version of the WHO interim guidance ⁷. Mild disease was defined as an uncomplicated upper respiratory tract infection (URI) with potential non-specific symptoms (e.g. fatigue, fever, cough and others) that does not require hospitalization. Moderate disease was defined as the presence of lower respiratory tract disease or pneumonia without respiratory distress and/or the need for supplemental oxygen, without signs of severe pneumonia. Severe disease was defined as severe lower respiratory tract infection or pneumonia with fever plus any one of the following: tachypnea (respiratory rate > 30 breaths per minute), respiratory distress, or oxygen saturation less than 93% on room air, or PaO2/FiO2 ratio < 300. Critical disease is defined as the need for intensive care unit admission or the presence of acute respiratory distress syndrome (ARDS), sepsis, or septic shock ⁷.

IGRA testing

In our region, the two main indications for requesting IGRA testing are TB contact-tracing and diagnosis of LTBI in immunosuppressed patients and/or candidates for biological therapies ^{8,9}.

QFT-Plus was performed as recommended by the manufacturer (Qiagen GmbH, Hilden, Germany). A cut-off level of IFN- $\gamma \geq 0.35$ IU/ml in TB1 (includes peptides ESAT-6 and CFP10 modified to stimulate CD4 + T cells) and/or TB2 (includes peptides ESAT-6 and CFP10 modified to stimulate both CD4 + and CD8 + T cells) tubes and $\geq 25\%$ than nil tube (negative control) is interpreted as a positive QuantiFERON (QFT) test result. We defined a low IFN- γ response to PHA in the QFT tests by an IFN- γ concentration ≥ 0.50 IU/mL (minimum level required by the manufacturer for a valid IGRA result) in the mitogen tube (positive control, includes PHA to stimulate T cells) and less than 50% below the average values of the majority of samples processed in the same batch. A very low IFN- γ response to PHA was defined by IFN- γ concentration < 0.50 IU/mL in the mitogen tube.

Immune phenotyping

Peripheral blood cells were surface-stained with anti-CD45-FITC/CD16+56-RD1/CD19-ECD/CD3-PC5 (Beckman Coulter, Brea, CA, USA) to define lymphocyte subsets, and anti-CD45RA-FITC, anti-CD8-PE, anti-CCR7-APC (Biolegend, San Diego, CA, USA) anti-CD3-ECD (Beckman Coulter), anti-CD4-PerCP (BD Bioscience, San Jose, CA, USA) to define differentiation degree of T lymphocytes. One hundred microliters of peripheral whole blood from volunteers were stained with different combinations of labeled monoclonal antibodies for 20 min at room temperature. Samples were redblood lysed with FACS Lysing Solution (BD Biosciences), washed in PBS, and analyzed using Kaluza software in a Navios cytomeJ.-J. Palacios-Gutiérrez, A. Rodríguez-Guardado, M. Arias-Guillén et al.




Figure 1. Low IFN- γ Response to Phytohemagglutinin (PHA) in QuantiFERON TB Gold Plus (QFT) Assays and COVID-19 Pandemic Evolution in the Principado de Asturias (Spain) from Spring of 2020 to Autumn of 2021 (Source: ASTURSALUD (www.astursalud.es), Principado de Asturias). A) Figure shows IFN- γ response to PHA measured in the mitogen tube of QFT assay in patients from January 2018 to October 2021 (27,480 patient-samples). Blue line: Patients with very low IFN- γ response to PHA (IFN- γ concentration (minus nil) in mitogen tube < 0.5 IU/mL; QFT indeterminate result). Red line: Patients with low IFN- γ response to PHA (IFN- γ concentration (minus nil) = 0.5 IU/mL in mitogen tube and less than 50% below the average values). Red and blue arrows indicate the historically maximal rate (%) of low and very low response to PHA (%) in relationship with the onset of the COVID-19 pandemic. Green line indicates % of patients with QFT-positive results. B) Figure shows distribution of the 27,480 QuantiFERON assays performed per month from January 2018 to October 2021 (monthly average = 604.2; range: 398-842).

ter (Beckman-Coulter, Brea, CA, USA). Appropriate isotype control antibodies were used for marker settings.

Statistical analysis

Correlations between variables were assessed using the nonparametric Spearman test. Analyses were performed using the PASW Statistics 17.0 statistical software package (IBM SPSS, NY, USA), and P-values of 0.05 or less were considered significant.

Results

QFT-Plus results over time during the COVID-19 pandemic

Since December 2019, we noted a significant increase in the number of samples with low IFN- γ responses to PHA in the mitogen tube (positive control) of the QFT-Plus assay with peaks overlapped with the COVID-19 epidemics waves registered in our region from

March 2020 to October2021. This affected both the rate of very low (<0.50 IU/mL) and low (>0.50 IU/mL and less than 50% below the average values) IFN- γ response to PHA which respectively had never exceeded from 3% and 5% in the past (Figure 1A). The rate of indeterminate OFT-Plus results went from our historical average of 1.4% (from July 1, 2016, to November 30, 2019 [out of a total of 23,134 patients]) to 4.2% (from December 1, 2019, to October 31, 2021 [out of a total of 13,375 patients]). Specifically, 505 samples yielded indeterminate QFT-Plus results in that time period. There were no technical problems identified ¹⁰ or changes in testing practices that could explain these unexpected results. Of note, the number of QFT-Plus tests performed (Figure 1B) and patients with positive QFT-Plus results remained virtually unchanged before (March to November 2019) and during the pandemic (March 2020 to October 2021) (13.95% vs. 12.2%, respectively) (Figure 1A). The corresponding graphics to COVID-19 deaths evolution and from the number of patients with low IFN-gamma response to PHA in mitogen tube of QFT overlapped in time (Figure 2).




Figure 2. Evolution Over time of COVID-19 Deaths and of Patients with Low IFN-gamma Response to Phytohemagglutinin (PHA) in Mitogen Tube of QuantiFERON TB Gold Plus (QFT).

Analysis of hospitalized patients with suspected or confirmed COVID-19 pneumonia

We studied a cohort of 90 sequentially hospitalized patients for two weeks in March 2020 (first epidemic wave) with suspected COVID-19 (33 patients had clinical and/or radiological evidence of pneumonia, or acute respiratory distress but with negative RT-PCR for SARS-CoV-2 results) or confirmed COVID-19 (57 patients with positive RT-PCR for SARS-CoV-2 results). There were 48 adult men and 42 women, and the average age was 63.9 vears old (range 28-89). According to the WHO case definition. 68 patients (75.5%) presented mild/moderate disease (37 were RT-PCR-positive for SARS-CoV-2) and 22 (24.4%) severe/critical disease (20 were RT-PCR-positive test, P<0.05). Underlying comorbidities included hypertension (23%), diabetes mellitus (11%), chronic obstructive pulmonary disease (9%), ischemic heart disease (7%), and asthma (6%). We compared the clinical and laboratory characteristics of two groups of patients in accordance with RT-PCR SARS-CoV-2 results (Table 1). Statistical significant differences were observed in the number of days since symptoms onset, lymphocyte count, alanine aminotransferase, lactate dehydrogenase, and mitogen tube response (P < 0.05).

A total of 49 out of 90 patients (54.4%) showed low or very low IFN- γ response to PHA, including 16 with QFT-Plus indeterminate results (due to very low IFN- γ response to PHA) and another 33 patients who, although they met the manufacturer criteria to validate the QFT results as negative (N = 29) or positive (N = 4), showed low IFN- γ response to PHA. The age range was very similar in both groups (17 and 32 patients vs. 17 and 24 patients, for <65 years old and elderly respectively). In Table 2, we compared both the RT-PCR SARS-CoV-2 results and the response to PHA in the QFT assay. Abnormal radiological findings but no disease severity or other laboratory abnormalities showed statistical significance association with low mitogen response in the QFT assay. No patients received immunosuppressive drugs prior to the blood collections for the QFT assay.

Immune profiling in a subgroup of elderly patients with COVID-19 in the prospective cohort

We studied seventeen elderly patients (fifteen of them lived in the same nursing home) that were admitted to the hospital for observation after being diagnosed of COVID-19. Study subjects underwent serial blood testing for QFT and whole-blood immune profiling. We found that production of IFN- γ in whole blood stimulated with PHA varied greatly in these COVID-19 patients. We quantified the different lymphocyte subsets to attempt to identify cells associated with abnormal IFN- γ response to PHA. PHA is a polyclonal activator of T-cells and thus, B and NK-cell counts were not related to IFN- γ production. The number of CD4 + T-cells subsets also did not correlate with IFN-y response to PHA in these patients; however, the total number of CD8+T-cells showed an statistical significant correlation with IFN- γ levels (rho = 0.491, P = 0.04) (Figure 3A). Then, we analyzed functionally different populations of T-cells separated by using combinations of cell surface markers CD45RA and the chemokine receptor CCR7. Using these markers, we subdivided the T-cells into naïve (naïve, CD45RA + CCR7 +), central memory (CM, CD45RA-CCR7 +), effector memory (EM, CD45RA-CCR7-), and effector memory RA (EMRA, CD45RA+CCR7-) from less to more differentiated T cell stages ¹¹ (Figure 3B). The analysis of the CD4+T-cells subsets revealed no statistically significant correlations; however, the number of EMRA CD8 + T-cells also showed an statistical significant correlation with IFN-y response levels to PHA in whole blood of these patients with COVID-19 and abnormal QFT-Plus results (rho = 0.540, P = 0.03).

Ten out of seventeen study patients had a follow-up QFT testing and immune profiling a week later (Table-3; Figure 3C). A statistical significant positive correlation was again observed with EMRA CD8 + T-cell counts and IFN- γ response levels to PHA (data not shown). In those patients with more than 100 EMRA CD8 + Tcells/ μ L (5 out 10), the increase or decrease in the levels of IFN- γ and in this lymphocyte subpopulation occurred in the same direction. On the contrary, those patients with less than 100 cells/ μ L

Table 1

Prospective Cohort, Patients Characteristics (N = 90).

	Suspected COVID-19 pneumonia with negative or indeterminate COVID-19 testing ^a No. (%)	Laboratory-confirmed COVID-19 pneumonia No. (%)	<i>P</i> value ^{a,b}	
Demographic information				
Total No.	33	57		
Age, Mean [SD]	59.5 [17.7]	66.5 [11.7]	0.05	
Sex	16(495)	22 (50.1)	0.51	
Male Female	16 (48.5) 17 (51.5)	32 (56.1) 25 (43.9)	0.51	
Temule	17 (51.5)	25 (45.5)		
ymptoms				
Days since symptoms onset, Mean [SD]	5.81 [3.74]	7.17 [2.59]	0.04	
Upper airways symptoms	23 (69.7)	49 (86.0)	0.12	
Fever	20 (60.6) 19 (57.6)	45 (78.9) 37 (64.9)	0.20 0.81	
Dyspnea Syncope	3 (9.1)	2 (3.5)	0.34	
	5 (011)	2 (0.0)	0101	
omorbidities	40 (20.2)	20 (25 4)	0.01	
Hypertension	10 (30.3)	20 (35.1)	0.81	
Diabetes Mellitus	10 (30.3)	8 (14.0)	0.06	
adiological findings				
Normal ^c	6 (18.2)	6 (10.5)		
Unilateral infiltrate	9(27.3)	36 (63.2)	< 0.01	
Bilateral infiltrate	18 (54.5)	15 (26.3)		
aboratory findings				
Leucocyte counts				
Mean [SD]	9440 [6450]	6330 [2690]	0.05	
Missing	4(12.1)	2 (3.5)		
Lymphocyte count Mean [SD]	2150 [2920]	1000 [652]	0.04	
Missing	9 (27.3)	7 (12.3)	0.04	
Aspartate aminotransferase, U/L ($4.0 - 41.0$)	5 (21.5)	, (12.5)		
Mean [SD]	98.7 [179]	49.5 [33.4]	0.94	
Missing	24 (72.7)	35 (61.4)		
Alanine aminotransferase, U/L (4·0 – 41·0)				
Mean [SD]	61.6 [113]	56.5 [40.7]	0.04	
Missing	9 (24.3)	9 (15.8)		
Lactate dehydrogenase, U/L ($40.0 - 480.0$)	420 [202]	F29 [222]	0.02	
Mean [SD] Missing	438 [202] 8 (24.2)	538 [232] 6 (10.5)	0.03	
<i>C</i> -reactive protein, $mg/L(0.0 - 5.0)$	0(24.2)	0(10.5)		
Mean [SD]	74.0 [59.1]	83.0 [73.5]	0.87	
Missing	1 (3.0)	5 (8.8)		
Procalcitonin, ng/mL $(0.0 - 0.50)$				
Mean [SD]	0.727 [1.30]	0.244 [0.426]	0.31	
Missing	22 (66.7)	36 (63.2)		
Fibrinogen, mg/dL (150.0 – 600.0)	CO2 (FO 2)	C40 [12C]	0.00	
Mean [SD] Missing	692 [59.2] 25 (75 8)	649 [136] 22 (56 1)	0.29	
Missing D-dimer, ng/mL (208·0 – 500·0)	25 (75.8)	32 (56.1)		
Mean [SD]	1220 [1480]	989 [901]	0.94	
Missing	10 (30.3)	10 (17.5)	0.01	
Ferritin, ng/mL (30·0 – 400·0)	· · /	× ,		
Mean [SD]	633 [621]	789 [578]	0.15	
Missing	16 (48.5)	27 (47.4)		
reatment ^d				
HCQ	17 (51.5)	48 (84.2)		
AZM	17 (51.5)	47 (82.4)		
LPV/RTV	16 (48.4)	49 (85.9)		
CRO	0(0)	35 (61.4)		
LFX	0(0)	6 (10.5)		
BMPr	0(0)	12 (21.0)		
IFN TOZ	0 (0) 0 (0)	5 (8.7) 5 (8.7)		
	0(0)	5 (6.7)		
)FT results in each tube, IU/mL				
Nil tube	0.207 [0.75.4]	0.124 [0.100]	0.50	
Mean [SD] Tb1 tube	0.297 [0.754]	0.124 [0.106]	0.52	
Mean [SD]	0.979 [2.25]	0.512 [1.26]	0.17	
incuit [50]	0.575 [2.25]	0.512 [1.20]	0.17	

J.-J. Palacios-Gutiérrez, A. Rodríguez-Guardado, M. Arias-Guillén et al.

Table 1 (Continued)

	Suspected COVID-19 pneumonia with negative or indeterminate COVID-19 testing ^a No. (%)	Laboratory-confirmed COVID-19 pneumonia No. (%)	P value ^{a,b}
Tb2 tube Mean [SD] Mitogen tube	0.985 [2.27]	0.557 [1.38]	0.81
Mean [SD]	5.04 [2.80]	3.35 [2.80]	0.03

Abbreviations: PHA, phytohemagglutinin; HCQ, hydroxychloroquine; AZM, azithromycin; LPV/RTV, lopinavir/ritonavir; CRO, ceftriaxone; LFX, levofloxacin; BMPr, bolus 6-methylprednisolone; IFN, interferon alpha-2b; TOZ, tocilizumab; QFT, QuantiFERON[™] TB Gold Plus.

^a Suspected COVID-19 pneumonia was based on clinical and/or radiological evidence of pneumonia, or acute respiratory distress but with negative or indeterminate RT-PCR for SARS-CoV-2 results from respiratory specimens during the first peak of COVID-19 pandemic in Asturias (March 2020).

^b *P*-value comparison between patients with negative/indeterminate vs. positive RT-PCR for SARS-CoV-2 results for both groups by the Fisher's Exact test or r x c Exact contingency, or by the Wilcoxon rank test when appropriate.

^c Diagnosis by chest computed tomography (CT).

^d Drug combination, one or more of the drugs listed were administered together.




Figure 3. Immunophenotyping of Lymphocytes and T Cell Subsets and IFN-Y Level Responses to Phytohemagglutinin (PHA).

A) Pearson correlations between lymphocyte subsets counts and IFN- γ level responses to PHA in whole blood of patients with COVID-19 pneumonia, including statistical significant correlations in CD8 T-cell counts and IFN- γ level responses to PHA (lower right-side quadrant; P < 0.05). B) Statistical significant positive correlations in EMRA CD8 T-cell counts and IFN- γ level responses to PHA (lower right-side quadrant; P < 0.05). B) Statistical significant positive correlations in EMRA (D8 T-cell counts and IFN- γ level responses to PHA (lower right-side quadrant; P < 0.05). C) EMRA CD8 + T-cell Counts (solid line with triangles) and IFN- γ Response Levels (IU/mL) to PHA (dashed line with squares) at Days 1 and 7 After Hospital Admittance of Ten QFT-monitored Patients (named A to J). Their Clinical Evolution is Also Included. Left, 5 patients with initial normal response to PHA at day 1 (four of them had low/very low response to PHA at day 7); Right, 5 patients with initial low/very low response to PHA at day 1 (three of them had normal response to PHA at day 7).

showed no recovery in either the number of cells or IFN- γ response levels to PHA (Figure 3C).

Discussion

Since December 2019, we observed an unprecedented increase in the rate of low IFN- γ responses to PHA in the QFT-Plus assay. These abnormal immune response findings were especially pronounced during the first four waves of the COVID-19 epidemic in our region from March to May 2021 (Figure 1A), suggesting that the findings were related to biologic effects of COVID-19. We have also observed that this low mitogen response in the QFT assay is more often present in patients with confirmed COVID-19 pneumonia compared with patients with suspected COVID-19 pneumonia but with negative RT-PCR test for SARS-CoV-2 virus, further supporting the association between COVID-19 and low mitogen responses. Further, subgroup analysis showed that the presence of chest xray abnormalities were associated with abnormal QFT mitogen response in our univariate analysis, again suggesting that the low

Table 2

Prospective Cohort, PHA Responses in QFT	by Radiological, COVID-19 Disease Severity	, and Laboratory Abnormalities Accord	1 to RT-PCR SARS-CoV-2 Results.

	Number of patients included	RT-PCR-SARS-CoV-2 results	PHA normal response	PHA low/very low response	<i>P</i> value ^c	QFT-Positive			
Chest radiograph	Chest X-rays findings	51 Positive	19	32		6 (1 PHA normal, 5 PHA			
= 90	of pneumonia	4 Indeterminate	1	3	0.01 ^d	low/very low)			
	78/90	23 ^b Negative	15	8 ^b		1 (1 PHA normal)			
	,0,50	25 Hegalive	15	0		2 (2 PHA normal)			
	Normal chest	6 Positive	1	5		1 (1 PHA low/very low)			
		2 Indeterminate	2	0	0.11	0			
	radiograph				0.11				
	12/90	4 Negative	3	1		1 (1 PHA normal)			
OVID-19 disease	Mild/Moderate disease	37 Positive	17	20		5 (1 PHA normal, 4 PHA			
everity	68/90	6 Indeterminate	3	3	0.38	low/very low)			
= 90		25 Negative	16	9		1 (1 PHA normal) 3 (1 PHA normal)			
	Severe/Critical disease	20 Positive	4	16		2 (2 PHA low/very low)			
	22/90	0 Indeterminate	0	0	1.00	0			
	,	2 Negative	0	2		0			
ymphocyte count	≥1.0	20 Positive	11	9		2 (2 PHA low/very low)			
10 ⁹ L)	33/74	2 Indeterminate	0	2	0.48	0			
	55/74				0.40				
=74		11 Negative	5	6		1 (1 PHA normal)			
	< 1.0	31 Positive	8	23		5 (1 PHA normal, 4 PHA			
	41/74	2 Indeterminate	1	1	0.23	low/very low)			
		8 Negative	4	4		0			
	100 / I		_	20		0			
erritin	\geq 400 ng/mL	27 Positive	7	20		5 (1 PHA normal, 4 PHA			
= 47	35/47	1 Indeterminate	0	1	0.24	low/very low)			
		7 ^a Negative	4	3 ^a		0			
						0			
	<400 ng/mL	4 Positive	4	0		0			
	12/47	2 Indeterminate	0	2	0.09	0			
		6 Negative	4	2		2 (1 PHA normal, 1 PHA low/very low)			
D-dimer	$\geq 1 \text{ ng/mL}$	19 Positive	3	16		5 (1 PHA normal, 4 PHA			
= 70	25/70	0 Indeterminate	0	0	0.12	low/very low)			
-70	25/70		3	3ª	0.12	0			
		6 ^a Negative	5	5		1 (1 PHA normal)			
	1		15	10		, , , ,			
	<1 ng/mL	28 Positive	15	13		2 (1 PHA normal, 1 PHA			
	45/70	3 Indeterminate	1	2	0.63	low/very low)			
		14 ^a Negative	9	5 ^a		0			
						0			
rocalcitonin	\geq 0.5 ng/mL	2 Positive	0	2		0			
= 32	4/32	0 Indeterminate	0	0	1.00	0			
		2 Negative	0	2		0			
	< 0.5 ng/mL	19 Positive	6	13		3 (1 PHA normal, 2 PHA			
	28/32	3 Indeterminate	2	1	0.51	low/very low)			
	-,	6 Negative	3	3		0			
		STICGUITE	5	5		1 (1 PHA normal)			
lanine	\geq 40 U/L	26 Positive	9	17		4 (1 PHA normal, 3 PHA			
			0		0.22				
minotransferase	35/72	1 Indeterminate		1	0.22	low/very low)			
=72		8 Negative	5	3		0			
	<40 U/L	22 Positive	10	10		1 (1 PHA normal)			
	'		10	12	0.01	3 (3 PHA low/very low)			
	37/72	1 Indeterminate	0	1	0.61	1 (1 PHA normal)			
		14 Negative	8	6		1 (1 PHA normal)			
actate dehydrogenase	≥480 U/L	25 Positive	5	20		4 (1 PHA normal, 3 PHA			
= 76	32/76	1 Indeterminate	0	1	0.62	low/very low)			
		6 Negative	0	6		0			
						0			
	< 480 U/L	26 Positive	15	11		3 (3 PHA low/very low)			
	44/76	3 Indeterminate	1	2	0.15	0			
		15 Negative	12	3		1 (1 PHA normal)			

Abbreviations: PHA, phytohemagglutinin; QFT, QuantiFERON TB Gold Plus; PHA very low, very low IFN-gamma response to PHA when IFN-gamma concentration (minus Nil) in mitogen tube < 0.5 IU/mL; PHA low, low IFN-gamma response to PHA when IFN-gamma concentration (minus Nil) \geq 0.5 IU/mL in mitogen tube and less than 50% below the average values; PHA normal, normal IFN-gamma response to PHA when IFN-gamma concentration (minus Nil) \geq 0.5 IU/mL in mitogen tube and at least more than half of the average value.

^a One patient with positive serum anti-SARS-CoV-2 IgG-IgM results.

^b Two patients with positive serum anti-SARS-CoV-2 IgG-IgM results.

^c P value for comparison of clinical, radiological or laboratory findings between group with normal vs. low-response to PHA in QFT assay in patients with confirmed COVID-19 pneumonia diagnosis (i.e. positive RT-PCR and/or serum anti-SARS-CoV-2 IgG-IgM results) and patients with negative or indeterminate RT-PCR SARS-CoV-2 test results by the r x c Exact contigency test.

^d *P*=0.01 for comparison of frequency of abnormal chest X-ray findings between group with normal vs. low-response to PHA in QFT assay in patients with both suspected and confirmed COVID-19 pneumonia diagnosis by the r x c Exact contingency test.

Table 3
Clinical Data From 10 (named A to J) Patients* With Follow-up QuantiFERON TB Gold Plus During COVID-19 Pandemic.

656

Patient ID	• •	Chest X-rays findings	Gender	Age	Comorbidity	PO2 sat. %	Flu- vaccine	RT-PCR SARS- CoV-2	PHA response Day 1 Day 3 Day 7	Leucocytes Day 1 - Day 7	Lympho- cytes Day 1 - Day 7	QFT	D- dimer	LDH	Ferritin	Procalci- tonin	ALT	Treatmen
A	Asymptomatic	Basal right infiltrate	Female	83	UTIs	92	yes	Pos	7.61 Normal	5590	960	Pos	3524	199	180	0.06	21	HCQ
									2.65 Low	-	-							AZM
	Abdominal pain	Bilateral infiltrate	Female	76	Diabetes	97	yes	Pos	2.67 Low 6.97 Normal	3340 4210	360 900	Neg	1033	260	733	0.05	24	Non- specific treatment
					HTN Psoriasis				2.95 Low 1.97 Low	- 4010	- 840							
С	Myalgia	Bilateral infiltrate	Male	56	CRF None	93	yes	Pos	5.61 Normal	2650	270	Neg	228	Ν	578	0.08	19	HCQ
	Fever								1.04 Low	-	-							AZM
									0.69 Very Low	5230	430							LPV/RTV
D	Fever	Basal left infiltrate	Female	91	Atrial fibrillation arrhythmia	98	yes	Pos	5.31 Normal	5930	1260	Neg	5583	N	198	0.08	7	HCQ
					Osteoporosis				5.66 Normal	-	-							AZM
									4.33 Normal	7620	1420							
E	Asymptomatic	Bilateral infiltrate	Female	85	Diabetes type 2 HTN	97	yes	Pos	4.51 Normal 2.98 Low	2840	810	Pos	269	227	529	0.1	21	HCQ.
					CRF Basal cell carcinoma				2.98 LOW 1.04 Very Low	3520	- 680							
F	Dyspnea	Bilateral infiltrate	Male	86	Prostate cancer	95	yes	Neg	3.68 Low	4530	1380	Neg	3274	345	223	0.07	18	HCQ
					Ictus			(IgM/ IgG pos)	2.98 Low	-	-							LPV/RTV
					CRF HTN				0.30 Very Low	7180	1610							CRO
G	Asymptomatic	Bilateral infiltrate	Female	91	Ischemic car- diomyophaty Ovarian	95	yes	Pos	3.28 Low 0.18 Very Low	4120 -	1860	Pos	547	326	NR	0.09		HCQ LFX
					cancer				0.10 Very Low									LIX
									7.87 Normal	9380	1910							
H	Cough	Bilateral infiltrate	Female	74	HTN	98	yes	Pos	2.93 Low	5370	1350	Neg	6367	211	122	0.04	13	HCQ
					Primary hypothy- roidism				5.75 Normal	-	-							AZM
					D : 1				8.12 Normal	6390	2060				100	0.00		LPV/RTV
I	Asymptomatic	Rx normal findigns	Female	81	Diabetes type 2 HTN	95	yes	Pos	0.83 Low 4.53 Normal	7600	1100	Neg	6327		408	0.06	17	HCQ AZM
									8.15 Normal	5400	1470							. 12.171
J	Asymptomatic	Bilateral infiltrate	Male	71	HTN	100	yes	Pos	0.07 Very Low	5350	1830	Pos	2524	169	838	0.42	15	HCQ
					Hyperuricemia				0.19 Very Low	-	-							AZM
					Biliary cirrhosis Ischemic car- diomyophaty				0.14 Very Low	5260	1220							

Abbreviations: Rx, chest X-rays; HTN, hypertension; CRF, chronic renal failure; UTIs, urinary tract infections; PHA, phytohemagglutinin; QFT, QuantiFERON TB Gold Plus; LDH, lactate dehydrogenase; ALT, alanine aminotransferase; Pos, positive; Neg, negative; N, normal; HCQ, hydroxychloroquine; AZM, azithromycin; LPV/RTV, lopinavir/ritonavir; CRO, ceftriaxone.

* Nine of them lived in the same nursing home and were admitted to the hospital for observation after being diagnosed of COVID-19.

Archivos de Bronconeumología 58 (2022) 649-659

 $\ensuremath{\mathsf{IFN}}\xspace \gamma$ responses to PHA were associated with true COVID-19 pneumonia.

Other studies have also reported a similar increase frequency of low IFN- γ response to mitogen and indeterminate QFT results in hospitalized patients with COVID-19, including patients with severe and critical COVID-19 and hyperinflammatory syndrome ^{12,13}. Interestingly, indeterminate QFT results were more frequent among COVID patients who died during hospitalization in a retrospective study from Spain (29.1% vs. 64.7%) ¹³, but these abnormal QFT results were not associated with increased mortality in a study from the United States ¹². However, these studies did not adjust these survival analyses to other known factors associated with increased mortality in COVID-19, including older age, male sex, and various comorbidities ¹⁴.

Reduced IFN- γ responses to PHA stimulation are common in certain clinical scenarios. Most often, they are observed in immunosuppressed patients, both those with underlying immunodeficiency and those on immunosuppressive treatments ^{15,16}. Importantly, none of the patients in our cohort received immunosuppressive drugs for the treatment of COVID-19 prior to undergoing IGRA testing. Specific immune dysfunctions are also well-established to increase the rate of indeterminate IGRA tests, including the low CD4 counts of HIV and the T cell exhaustion exhibited among critically-ill patients and patients with active lupus erythematosus ^{17,18}. However, in our study, patients with low IFN- γ responses did not have reduced CD4 counts, and we did not find an association between severity of COVID-19 and low mitogen response, which argues against T-cell exhaustion. However, T-cell exhaustion and complex immune activation are common in patients with COVID-19 pneumonia, and we cannot exclude these pathophysiological factors playing a role ¹⁹. In addition, in patients with inflammatory bowel disease, low serum albumin, lymphopenia, and corticosteroid therapy have been associated with increased odds to have indeterminate IGRA results with low mitogen response in a multivariate analysis ²⁰. In our study, we did not analyze serum albumin levels but the presence of lymphopenia had a trend towards statically significant association with a low mitogen response in the QFT assay. Another study with critical COVID-19 patients found no direct association between lymphopenia, inflammatory markers, or severity of COVID-19 with QFT indeterminate results ¹²; however, some of those critically-ill COVID-19 patients received immunosuppressive treatments, which was not a cofounder in our study. Occasionally, indeterminate response can be seen related to technical problems inherent to the assay variability of any immunodiagnostic test (pre-analytical, analytical and post-analytical phases). However, we were unable to identify any analytical laboratory factor or patient-related immunosuppressive factors to explain these study laboratory findings.

In our prospective study cohort with T cell immune profiling data, a reduction in total CD8 T cell counts and differentiated CD8 EMRA T-cell subset were statistically associated with the observed reduction in IFN-y responses to PHA stimulation in the QFT-Plus assay. Lymphopenia with preferential peripheral blood CD8 + T-cell reduction has been described in COVID-19, but the mechanism of the observed frequent reduction in IFN- γ responses to PHA activation in the QFT-Plus assay is not entirely clear ²¹. Recent reports suggest the presence of T cell and NK cell dysfunction and exhaustion phenotypes associated with a hyperactivation immune state during COVID-19. This phenomenon is suggested by overexpression of CD69, a marker of activation, and TIM-3 on NK, CD4 and CD8 T cells. TIM-3 is a negative regulator of immune cell function and its ligands induces T and NK cell exhaustion in viral infections ²². Along these lines, another study showed that a small subset of critically-ill COVID-19 patients with indeterminate QFT results had increased IL-10 levels and reduced Th1-related cytokine

levels, which the authors suggest a relationship with Th2 immune responses in this setting. However, recent immune profiling data in patients with COVID-19 pneumonia showed not only increase Th2 response can be observed but also a global immune and inflammatory activation process that includes complex immunoregulatory mechanisms and T-cell exhaustion that can affect Th1-immune response, including IFN- γ responses to activating factors ¹⁹. In addition, there is CD8 T cell dysfunction in elderly patients with COVID-19, and EMRA CD8+T-cell subsets also display a senescence-associated secretory phenotype that may contribute to age-related inflammation in COVID-19^{23,24}. Interestingly, there was a trend towards an older age in the study group with low mitogen response in the QFT compared with the group with normal mitogen response in our study (Table 1). In this context, there are increasing numbers of reported cases of COVID-19 and TB coinfection ^{25,26}. In fact, there is also a concern that viral infections, including COVID-19, could have a pathophysiologic effect on TB progression and TB reactivation in LTBI ^{27–30}. However, the clinical implications of these abnormal CD8+T cell responses associated with COVID-19 for other infections, including potential for TB reactivation in the future, are unclear at this time of the pandemic.

Importantly, some experts suggested that the use of IGRA to screen for TB infections in patients with severe COVID-19 has limited value^{11,31}. Our study results show the overall number of patients with a positive QFT result remained unchanged before and during the pandemic (13.95% vs. 12.2%, respectively). We also did not find there any significant difference in rates of "positive" response to the QFT Mtb specific antigens in those patients with low/very low PHA response in the mitogen tube before and during the pandemic (6.2% vs. 7.9%; and 1.3% vs. 2.1%; for low and very low response to PHA, respectively). Moreover, some of our hospitalized COVID-19 patients showed "positive" Mtb antigenspecific responses (>0.35 IU/mL) despite transiently or persistent low response to mitogen in repeat QFT testing (Table 3). Overall, our results suggest considering repeating QFT testing in 3-7 days in patients with COVID-19 pneumonia with risk factors for Mtb infection, particularly in those patients with "positive" Mtb specific antigen response.

Of note, the first confirmed COVID-19 case in Spain was officially reported in February 2020 but we observed an unexpected high rate of abnormal QFT mitogen response since December 2019 in our study. If our hypothesis holds true, our study laboratory findings also suggest that the COVID-19 epidemic may have started earlier in our region (Figure 1 A). This study finding also suggests that monitoring the rate of low mitogen response in the QFT-Plus assay can be utilized as an epidemiological screening tool for early detection of COVID-19 epidemics that could trigger more specific testing of suspected cases and undiagnosed patients with pneumonia in the community. The complexity (logistics and cost) inherent to a mass COVID-19 screening strategy is unquestionable. In our region, the results observed (at least with regard to the evolution of the number of deaths due to COVID-19 and the temporal correlation with the different pandemic waves) were, surprisingly, identical to those registered with about 2 million diagnostic tests performed for COVID-19 between March 2020 and October 2021, compared to 12,837 QFT assays (mean 642 test/month). Moreover, in contrast with previous epidemic waves, during the fifth wave, the number of cases with RT-PCR SARS-CoV-2 positive increased in our region, while severe cases and mortality were significantly reduced, and also the number of patients with low IFN-gamma response to PHA in the mitogen tube. This situation could be explained because in most cases were young people with mild symptoms, as well as by the high degree of vaccination coverage in our region. We think that these findings support the hypothesis of a potential population-based marker of COVID-19-related mortality but additional studies would be needed to determine if this marker is

sensitive and specific for early detection and prediction of COVID-19-related mortality at the population based level.

Our study has some potential limitations, including the observational nature of the study design and the relatively limited number of hospitalized patients studied in the cohort part of the study. A small number of subjects can lead to suboptimal power to differentiate true differences in the study subgroups. Multiple comparison analysis can also increase the risk of false discovery rates. However, we believe that our study cohort was representative of patients suspected of and confirmed COVID-19 pneumonia in our region during the first peak of the pandemic given the referral nature of our laboratory and hospital services. Our study also has several strengths, including the centralized nature of our laboratory services that allow us to capture the high frequency of QFT testing utilization and LTBI screening results in our entire region during the pandemic. In addition, our study benefited from the excellent epidemiological tracking of COVID-19 cases and their laboratory results in our region in Spain. In addition, the prospective nature of our multifactorial and immune profiling investigations is another important strength of our study.

In conclusion, our study findings suggest that low IFN- γ responses in the mitogen control tube of the QFT-Plus assay often occur in COVID-9 pneumonia, which can be utilized as a surveillance tool to track the COVID-19 pandemic waves. These abnormal QFT-Plus results were likely related to a suboptimal number and response of a subset of differentiated CD8 T cells to PHA associated with SARS-COV-2 infections. The clinical implications of these abnormal immune responses in COVID-19 for other infections, including the potential for an increase in TB reactivation rates in the future, are unclear at this time of the pandemic. However, this abnormal mitogen response does not seem to affect the IFN- γ response to specific Mtb antigens in COVID-19 patients, and thus, we propose to revisit and redefine the QFT-Plus indeterminate test results criteria in this setting.

Ethics approval:

Ethical clearance was approved by the Comité de Ética de la Investigación del Principado de Asturias, Spain

Transparency declaration:

The authors have no conflicts of interest to declare.

Funding:

None

References

- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–3, http://dx.doi.org/10.1038/s41586-020-2012-7.
- Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324:782–93, http://dx.doi.org/10.1001/jama.2020.12839.
- Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020;324:1307–16, http://dx.doi.org/10.1001/jama.2020.17021.
- Rodríguez-Baño J, Pachón J, Carratalà J, Ryan P, Jarrín I, Yllescas M, et al. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19) Clin Microbiol Infect. 2020 Aug 27;S1198–743X:30492-4, http://dx.doi.org/10.1016/j.cmi.2020.08.010. Online ahead of print.
- Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117:10970–5, http://dx.doi.org/10.1073/pnas.2005615117.

- World Health Organization. (2011). Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries: policy statement. (accessed June 2020). ISBN 978 92 4 150267 2. WHO/HTM/TB/2011.18. https://www.who.int/tb/publications/tb-igras-statement/en/.
- World Health Organization. (?2020)? Clinical management of COVID-19: interim guidance, 27 May 2020. World Health Organization. https://apps.who.int/iris/handle/10665/332196. License: CC BY-NC-SA 3.0 IGO (accessed June 2020).
- Arias-Guillén M, Sánchez Menéndez MM, Alperi M, Riestra S, González Budiño MT, García-Clemente MM, et al. High rates of tuberculin skin test positivity due to methotrexate therapy: False positive results? Semin Arthritis Rheum. 2018;48:538–46, http://dx.doi.org/10.1016/j.semarthrit.2018.03.018.
- Fernández Blázquez A, Argüelles Menéndez P, Sabater Cabrera C, García García JM, Asensi Álvarez V, Palacios Gutiérrez JJ. Diagnosis of Tuberculous Infection in Immunosuppressed Patients and/or Candidates for Biologics Using a Combination of 2 IGRA Tests: T-SPOT.TB/QuantiFERON TB Gold In-Tube vs T-SPOT.TB/QuantiFERON TB Gold Plus. Arch Bronconeumol. 2020 Jun 10;S0300–2896;30128–9, http://dx.doi.org/10.1016/j.arbres.2020.04.011 [published online ahead of print].
- Pai M, Denkinger CM, Kik V, Rangaka S, Zwerling M, Oxlade AO, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27:3–20, http://dx.doi.org/10.1128/CMR.00034-13.
- Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708–12, http://dx.doi.org/10.1038/44385.
- Ward JD, Cornaby C, Schmitz JL. Indeterminate QuantiFERON gold plus results reveal deficient interferon gamma responses in severely ill COVID-19 patients. J Clin Microbiol. 2021;59:e00811–821, http://dx.doi.org/10.1128/JCM. 00811-21.
- Solanich X, Fernández-Huerta M, Basaez C, Antolí A, Rocamora-Blanch G, Corbella X, et al. Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome. J Clin Med. 2021;10:918, http://dx.doi.org/10.3390/jcm10050918.
- Clouston SAP, Luft BJ, Sun E. Clinical risk factors for mortality in an analysis of 1375 patients admitted for COVID treatment. Sci Rep. 2021;11(23414), http://dx.doi.org/10.1038/s41598-021-02920-w.
- Shahidi N, Nancy Fu Y-T, Qian H, Bressler B. Performance of interferongamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:2034–42, http://dx.doi.org/10.1002/ibd.22901.
- Santin M, Muñoz L, Rigay D. Interferon-γ Release Assays for the Diagnosis of Tuberculosis and Tuberculosis Infection in HIV-Infected Adults: A Systematic Review and Meta-Analysis. PLoS ONE. 2012;7:e32482, http://dx.doi.org/10.1371/journal.pone.0032482.
- Huang C-T, Ruan S-Y, Tsai Y-J, Kuo P-H, Ku S-C, Lee P-L, et al. Effects of acute critical illnesses on the performance of interferon-gamma release assay. Sci Rep. 2016 Jan 25;6:19972, http://dx.doi.org/10.1038/srep19972.
- Ahn SS, Eun Park ES, Shim JS, Ha S-J, Kim BS, Min Jung SM, et al. Decreased ex vivo production of interferon-gamma is associated with severity and poor prognosis in patients with lupus. Arthritis Res Ther. 2017;19:193, http://dx.doi.org/10.1186/s13075-017-1404-z.
- Papay P, Eser A, Winkler S, Frantal S, Primas C, Miehsler W, et al. Predictors of indeterminate IFN-γ release assay in screening for latent TB in inflammatory bowel diseases. Eur J Clin Invest. 2011;41:1071–6, http://dx.doi.org/10.1111/j.1365-2362.2011.02502.x.
- 20. De Biasi S, Meschiari M, Gibellini L, Bellinazzi C, Borella R, Fidanza L, et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat Commun. 2020;11:3434, http://dx.doi.org/10.1038/s41467-020-17292-4.
- Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 2020; 369, eabc8511. https://www.science.org/doi/10.1126/science.abc8511.
- Varchetta S, Mele D, Oliviero B, Mantovani S, Ludovisi S, Cerino A, et al. Unique immunological profile in patients with COVID-19. Cell Mol Immunol. 2020 Oct 15:1–9, http://dx.doi.org/10.1038/s41423-020-00557-9, ahead of print.
- Westmeier J, Paniskaki K, Karaköse Z, Werner T, Sutter K, Dolff S, et al. Impaired cytotoxic CD8+T cell response in elderly COVID-19 patients. mBio. 2020;11:e02243–2320, http://dx.doi.org/10.1128/mBio.02243-20.
- Callender LA, Carroll EC, Bober EA, Akbar AN, Solito E, Henson SM. Mitochondrial mass governs the extent of human T cell senescence. Aging Cell. 2020;19:e13067, http://dx.doi.org/10.1111/acel.13067.
- Tadolini M, Codecasa LR, García-García JM, Blanc FX, Borisov S, Alffenaar JW, et al. Active tuberculosis, sequelae and COVID-19 coinfection: first cohort of 49 cases. Eur Respir J. 2020;56:2001398, http://dx.doi.org/10.1183/13993003.01398-20201.
- 26. Gupta N, Ish P, Gupta A, Malhotra N, Caminero JA, Singla R, et al. A profile of a retrospective cohort of 22 patients with COVID-19 and active/treated tuberculosis. Eur Respir J. 2020;56:2003408, http://dx.doi.org/10.1183/13993003.03408-2020.
- Sheerin D, Abhimanyu, Wang X, Johnson WE, Coussens A. Systematic evaluation of transcriptomic disease risk and diagnostic biomarker overlap between COVID-19 and tuberculosis: a patient-level meta-analysis. medRxiv. 2020, http://dx.doi.org/10.1101/2020.11.25.20236646. Preprint. Nov 26.
- Dangor Z, Izu A, Moore DP, Nunes MC, Solomon F, Beylis N, et al. Temporal Association in Hospitalizations for Tuberculosis Invasive Pneumococcal Disease

and Influenza Virus Illness in South African Children. PLoS ONE. 2014;9:e91464, http://dx.doi.org/10.1371/journal.pone.0091464.

- van der Zalm MM, Walters E, Claassen M, Palmer M, Seddon JA, Demers AM, et al. High burden of viral respiratory co-infections in a cohort of children with suspected pulmonary tuberculosis. BMC Infect Dis. 2020;20:924, http://dx.doi.org/10.1186/s12879-020-05653-9.
- 30. Mhimbira F, Hiza H, Mbuba E, Hella J, Kamwela L, Sasamalo M, et al. Prevalence and clinical significance of respiratory viruses and bacteria detected in tuberculosis patients compared to household contact controls in Tanzania: a cohort study. Clin Microbiol Infect. 2020;25:107, http://dx.doi.org/10.1016/j.cmi.2018.03.019, e1-107.e7.
- 31. Shier KL. Elevated Rates of Indeterminate Results on QuantiFERON-TB Gold Plus in COVID-19 Patients. J Clin Microbiol. 2021;59:e01414–1421, http://dx.doi.org/10.1128/JCM. 01414-21.